Ipilimumab, a human IgG1κ anti-CTLA4 monoclonal Antibody (mAb), which binds CTLA4 and blocks its interaction with ligand CD80/CD86, was the parent ICI approved in 2011 by the Food and Drug Administration (FDA) for first and second-line therapy of melanoma [22]. Here, CTLA4 is linked to melanoma.